Drug Encapsulation: Review of Niosomes for Promoting Antimicrobial Activity
Source abstract
Abstract
Nanotechnology has been used for drug encapsulation with the development of more effective and less toxic nanomedicines. Some currently used antimicrobials present problems with their physicochemical characteristics and the emergence of resistant microorganisms. Thus, encapsulating these drugs in nanocarriers would be a promising alternative to overcome these problems. This systematic review aims to evaluate the development of niosomes for encapsulation of antimicrobials, highlighting studies with in vitro and in vivo research. A search was performed in the MEDLINE/PubMed and Web of Science databases from 2011 to May 2021 with an exclusion, eligibility, and classification criteria. Twenty articles were selected to write this review. It was observed that the niosomes produced presented differences in physicochemical characteristics according to the non-ionic surfactant used. The evaluation of cell and animal assays revealed that niosomes presented a significantly higher antimicrobial efficacy when compared to the free drug. A reduction in toxicity could also be observed. Thus, the development of niosome-based nanomedicines has progressed over the years and is a promising strategy to increase therapeutic efficacy and reduce drug toxicity.
Source: expertdata · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advancements in Transdermal Drug Delivery · Advanced Drug Delivery Systems · Microencapsulation and Drying Processes
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (86)
Show source-provided references
1. Cavalcanti IDL, Nogueira MCBL (2020) Pharmaceutical nanotechnology: which products are been designed against COVID-19? J Nanopart Res 22(9):276. https://doi.org/10.1007/s11051-020-05010-610.1007/s11051-020-05010-6 ↗
2. Hashemi, B. et al. 2021. Emerging importance of nanotechnology-based approaches to control the COVID-19 pandemic; focus on nanomedicine iterance in diagnosis and treatment of COVID-19 patients. J Drug Deliv Sci Technol. 102967. https://doi.org/10.1016/j.jddst.2021.10296710.1016/j.jddst.2021.102967 ↗
3. Nadzir MM et al (2017) Size and stability of curcumin niosomes from combinations of Tween 80 and Span 80. Sains Malaysiana. 46(12):2455–2460. https://doi.org/10.17576/jsm-2017-4612-2210.17576/jsm-2017-4612-22 ↗
4. Elzoghby AO (2019) Pharmaceutical nanotechnology in Egypt: diverse applications and promising outcomes. Nanomedicine (Lond) 14(6):649–653. https://doi.org/10.2217/nnm-2018-042610.2217/nnm-2018-0426 ↗
5. Ghosh S et al (2019) Role of nanostructures in improvising oral medicine. Toxicol Rep 6:358–368. https://doi.org/10.1016/j.toxrep.2019.04.00410.1016/j.toxrep.2019.04.004 ↗
6. Böttger R et al (2020) Lipid-based nanoparticle technologies for liver targeting. Adv Drug Deliv Rev 154–155:79–101. https://doi.org/10.1016/j.addr.2020.06.01710.1016/j.addr.2020.06.017 ↗
7. Sett R et al (2020) Effect of temperature and salts on niosome-bound anti-cancer drug along with disruptive influence of cyclodextrins. Spectrochim Acta A Mol Biomol Spectrosc 234:118261. https://doi.org/10.1016/j.saa.2020.11826110.1016/j.saa.2020.118261 ↗
8. Gharbavi M et al (2018) Niosome: a promising nanocarrier for natural drug delivery through blood-brain barrier. Adv Pharmacol Sci 2018:6847971. https://doi.org/10.1155/2018/684797110.1155/2018/6847971 ↗
9. Li W et al (2014) Cancer nanoimmunotherapy using advanced pharmaceutical nanotechnology. Nanomedicine (Lond) 9(16):2587–2605. https://doi.org/10.2217/nnm.14.12710.2217/nnm.14.127 ↗
10. Sahu, T. et al. 2021. Nanotechnology based drug delivery system: current strategies and emerging therapeutic potential for medical science. J Drug Deliv Sci Technol. 63(2021), 102487. https://doi.org/10.1016/j.jddst.2021.10248710.1016/j.jddst.2021.102487 ↗
11. Seleci DA et al (2016) Niosomes as nanoparticular drug carriers: fundamentals and recent applications. J Nanomaterials 2016:7372306. https://doi.org/10.1155/2016/737230610.1155/2016/7372306 ↗
12. Bajwa N et al (2016) Pharmaceutical and biomedical applications of quantum dots. Artif Cells Nanomed Biotechnol 44(3):758–768. https://doi.org/10.3109/21691401.2015.105246810.3109/21691401.2015.1052468 ↗
13. Estanqueiro M et al (2015) New trends in pharmaceutical nanotechnology. Curr Pharm Des 21(36):5169–5171. https://doi.org/10.2174/138161282199915092909551610.2174/1381612821999150929095516 ↗
14. Alexander A et al (2016) Recent expansion of pharmaceutical nanotechnologies and targeting strategies in the field of phytopharmaceuticals for the delivery of herbal extracts and bioactives. J Control Release 241:110–124. https://doi.org/10.1016/j.jconrel.2016.09.01710.1016/j.jconrel.2016.09.017 ↗
15. Kheirollahpour M et al (2020) Nanoparticles Vaccine Dev Pharm Nanotechnol 8(1):6–21. https://doi.org/10.2174/221173850766619102416204210.2174/2211738507666191024162042 ↗
16. Raghu PK et al (2020) Evolution of nanotechnology in delivering drugs to eyes, skin and wounds via topical route. Pharmaceuticals (Basel) 13(8):167. https://doi.org/10.3390/ph1308016710.3390/ph13080167 ↗
17. Babadi D et al (2021) Biopharmaceutical and pharmacokinetic aspects of nanocarrier-mediated oral delivery of poorly soluble drugs. J Drug Deliv Sci Technol 62(2021):102324. https://doi.org/10.1016/j.jddst.2021.10232410.1016/j.jddst.2021.102324 ↗
18. Nene S et al (2021) Lipid based nanocarriers: a novel paradigm for topical antifungal therapy. J Drug Deliv Sci Technol 62(2021):102397. https://doi.org/10.1016/j.jddst.2021.10239710.1016/j.jddst.2021.102397 ↗
19. Tambe VS et al (2021) Topical lipid nanocarriers for management of psoriasis-an overview. J Drug Deliv Sci Technol 64(2021):102671. https://doi.org/10.1016/j.jddst.2021.10267110.1016/j.jddst.2021.102671 ↗
20. Danimayostu AA et al (2017) The effect of niosomal system (Span 60-cholesterol) on Diclofenac sodium preparation characteristics and Diclofenac sodium preparation of hydroxypropyl cellulose gel base (HPC). Res J Life Sci 4(1):10–17. https://doi.org/10.21776/ub.rjls.2017.004.01.2.10.21776/ub.rjls.2017.004.01.2. ↗
21. Osanloo M et al (2018) Niosome-loaded antifungal drugs as an effective nanocarrier system: A mini review. Curr Med Mycol. 4(4):31–36. https://doi.org/10.18502/cmm.4.4.384.10.18502/cmm.4.4.384. ↗
22. Bhardwaj P et al (2020) Niosomes: a review on niosomal research in the last decade. J Drug Deliv Sci Technol 56(2020):101581. https://doi.org/10.1016/j.jddst.2020.10158110.1016/j.jddst.2020.101581 ↗
23. Moghassemi S, Hadjizadeh A (2014) Nano-niosomes as nanoscale drug delivery systems: an illustrated review. J Control Release 185:22–36. https://doi.org/10.1016/j.jconrel.2014.04.01510.1016/j.jconrel.2014.04.015 ↗
24. Qtaish NAL et al (2020) Niosome-based approach for in situ gene delivery to retina and brain cortex as immune-privileged tissues. Pharmaceutics 12(3):198. https://doi.org/10.3390/pharmaceutics1203019810.3390/pharmaceutics12030198 ↗
25. Liu Y et al (2019) Nanotechnology-based antimicrobials and delivery systems for biofilm-infection control. Chem Soc Rev 48(2):428–446. https://doi.org/10.1039/C7CS00807D10.1039/C7CS00807D ↗
26. Ojemaye MO et al (2020) Nanotechnology as a viable alternative for the removal of antimicrobial resistance determinants from discharged municipal effluents and associated watersheds: a review. J Environ Manage 275:111234. https://doi.org/10.1016/j.jenvman.2020.11123410.1016/j.jenvman.2020.111234 ↗
27. Pelgrift RY, Friedman AJ (2013) Nanotechnology as a therapeutic tool to combat microbial resistance. Adv Drug Deliv Rev 65(13–14):1803–1815. https://doi.org/10.1016/j.addr.2013.07.01110.1016/j.addr.2013.07.011 ↗
28. Seil JT, Webster TJ (2012) Antimicrobial applications of nanotechnology: methods and literature. Int J Nanomedicine 7:2767–2781. https://doi.org/10.2147/IJN.S2480510.2147/IJN.S24805 ↗
29. Campos EVR et al (2020) How can nanotechnology help to combat COVID-19? Oppor Urgent Need J Nanobiotechnol 18(1):125. https://doi.org/10.1186/s12951-020-00685-410.1186/s12951-020-00685-4 ↗
30. Malaekeh-Nikouei B et al (2020) The role of nanotechnology in combating biofilm-based antibiotic resistance. J Drug Deliv Sci Technol 60(2020):101880. https://doi.org/10.1016/j.jddst.2020.10188010.1016/j.jddst.2020.101880 ↗
31. Negut I et al (2018) Treatment strategies for infected wounds. Molecules 23(9):2392. https://doi.org/10.3390/molecules2309239210.3390/molecules23092392 ↗
32. Nikaeen G et al (2020) Application of nanomaterials in treatment, anti-infection and detection of coronaviruses. Nanomedicine (Lond) 15(15):1501–1512. https://doi.org/10.2217/nnm-2020-011710.2217/nnm-2020-0117 ↗
33. Bhavana V et al (2020) COVID-19: Pathophysiology, treatment options, nanotechnology approaches, and research agenda to combating the SARS-CoV2 pandemic. Life Sci 261:118336. https://doi.org/10.1016/j.lfs.2020.11833610.1016/j.lfs.2020.118336 ↗
34. Page, M.J. et al. 2021. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 372, 160. https://doi.org/10.1136/bmj.n160.10.1136/bmj.n160 ↗
35. Cruz R et al (2018) Does the incorporation of zinc into calcium phosphate improve bone repair? Syst Rev Ceram Int 44(2):1240–1249. https://doi.org/10.1016/j.ceramint.2017.10.15710.1016/j.ceramint.2017.10.157 ↗
36. Akbari V et al (2013) Ciprofloxacin nano-niosomes for targeting intracellular infections: an in vitro evaluation. J Nanopart Res 15:1556. https://doi.org/10.1007/s11051-013-1556-y10.1007/s11051-013-1556-y ↗
37. Alam M et al (2013) Development, characterization and efficacy of niosomal diallyl disulfide in treatment of disseminated murine candidiasis. Nanomedicine 9(2):247–256. https://doi.org/10.1016/j.nano.2012.07.00410.1016/j.nano.2012.07.004 ↗
38. Barakat HS et al (2014) Vancomycin-eluting niosomes: a new approach to the inhibition of staphylococcal biofilm on abiotic surfaces. AAPS PharmSciTech 15(5):1263–1274. https://doi.org/10.1208/s12249-014-0141-810.1208/s12249-014-0141-8 ↗
39. Dwivedi A et al (2018) Layer-by-layer nanocoating of antibacterial niosome on orthopedic implant. Int J Pharm 547(1–2):235–243. https://doi.org/10.1016/j.ijpharm.2018.05.07510.1016/j.ijpharm.2018.05.075 ↗
40. El-Ela FI et al (2020) Treatment of Brucellosis in guinea pigs via a combination of engineered novel pH-responsive curcumin niosome hydrogel and Doxycycline-loaded chitosan-sodium alginate nanoparticles: an in vitro and in vivo study. AAPS PharmSciTech 21(8):326. https://doi.org/10.1208/s12249-020-01833-710.1208/s12249-020-01833-7 ↗
41. Ghafelehbashi R et al (2019) Preparation, physicochemical properties, in vitro evaluation and release behavior of cephalexin-loaded niosomes. Int J Pharm 569:118580. https://doi.org/10.1016/j.ijpharm.2019.11858010.1016/j.ijpharm.2019.118580 ↗
42. Gupta A et al (2014) Formulation and evaluation of a topical niosomal gel containing a combination of benzoyl peroxide and tretinoin for antiacne activity. Int J Nanomedicine 10:171–182. https://doi.org/10.2147/IJN.S7044910.2147/IJN.S70449 ↗
43. Haque F et al (2017) Anti-biofilm activity of a sophorolipid-amphotericin B niosomal formulation against Candida albicans. Biofouling 33(9):768–779. https://doi.org/10.1080/08927014.2017.136319110.1080/08927014.2017.1363191 ↗
44. Hedayati ChM et al (2021) Niosome-encapsulated tobramycin reduced antibiotic resistance and enhanced antibacterial activity against multidrug-resistant clinical strains of Pseudomonas aeruginosa. J Biomed Mater Res A 109(6):966–980. https://doi.org/10.1002/jbm.a.3708610.1002/jbm.a.37086 ↗
45. Khan S et al (2020) Nanoniosome-encapsulated levoflaxicin as an antibacterial agent against Brucella. J Basic Microbiol 60(3):281–290. https://doi.org/10.1002/jobm.20190045410.1002/jobm.201900454 ↗
46. Khazaeli P et al (2014) Anti-leishmanial effect of itraconazole niosome on in vitro susceptibility of Leishmania tropica. Environ Toxicol Pharmacol 38(1):205–211. https://doi.org/10.1016/j.etap.2014.04.00310.1016/j.etap.2014.04.003 ↗
47. Mahdiun F et al (2017) The effect of tobramycin incorporated with bismuth-ethanedithiol loaded on niosomes on the quorum sensing and biofilm formation of Pseudomonas aeruginosa. Microb Pathog 107:129–135. https://doi.org/10.1016/j.micpath.2017.03.01410.1016/j.micpath.2017.03.014 ↗
48. Mirzaie A et al (2020) Preparation and optimization of ciprofloxacin encapsulated niosomes: a new approach for enhanced antibacterial activity, biofilm inhibition and reduced antibiotic resistance in ciprofloxacin-resistant methicillin-resistance Staphylococcus aureus. Bioorg Chem 103:104231. https://doi.org/10.1016/j.bioorg.2020.10423110.1016/j.bioorg.2020.104231 ↗
49. Mohammadi S et al (2019) Niosomal Benzoyl peroxide and clindamycin lotion versus niosomal Clindamycin lotion in treatment of acne vulgaris: a randomized clinical trial. Adv Pharm Bull 9(4):578–583. https://doi.org/10.15171/apb.2019.06610.15171/apb.2019.066 ↗
50. Mostafavi M et al (2019) A novel niosomal combination of selenium coupled with glucantime against Leishmania tropica. Korean J Parasitol 57(1):1–8. https://doi.org/10.3347/kjp.2019.57.1.110.3347/kjp.2019.57.1.1 ↗
51. Mostafavi M et al (2019) Niosomal formulation of amphotericin B alone and in combination with glucantime: In vitro and in vivo leishmanicidal effects. Biomed Pharmacother 116:108942. https://doi.org/10.1016/j.biopha.2019.10894210.1016/j.biopha.2019.108942 ↗
52. Nazari-Vanani R et al (2018) Investigation of anti-leishmanial efficacy of miltefosine and ketoconazole loaded on nanoniosomes. Acta Trop 185:69–76. https://doi.org/10.1016/j.actatropica.2018.05.00210.1016/j.actatropica.2018.05.002 ↗
53. Parizi MH et al (2019) Antileishmanial activity of niosomal combination forms of Tioxolone along with Benzoxonium chloride against Leishmania tropica. Korean J Parasitol 57(4):359–368. https://doi.org/10.3347/kjp.2019.57.4.35910.3347/kjp.2019.57.4.359 ↗
54. Thakkar M, Brijesh S (2018) Physicochemical investigation and in vivo activity of anti-malarial drugs co-loaded in Tween 80 niosomes. J Liposome Res 28(4):315–321. https://doi.org/10.1080/08982104.2017.137668410.1080/08982104.2017.1376684 ↗
55. Zoghroban HS et al (2019) Niosomes for enhanced activity of praziquantel against Schistosoma mansoni: in vivo and in vitro evaluation. Parasitol Res 118(1):219–234. https://doi.org/10.1007/s00436-018-6132-z10.1007/s00436-018-6132-z ↗
56. Brovč EV et al (2020) Rational design to biologics development: the polysorbates point of view. Int J Pharm 581:119285. https://doi.org/10.1016/j.ijpharm.2020.11928510.1016/j.ijpharm.2020.119285 ↗
57. Cheng M et al (2018) Tween 80 surfactant-enhanced bioremediation: toward a solution to the soil contamination by hydrophobic organic compounds. Crit Rev Biotechnol 38(1):17–30. https://doi.org/10.1080/07388551.2017.131129610.1080/07388551.2017.1311296 ↗
58. Ionova Y, Wilson L (2020) Biologic excipients: importance of clinical awareness of inactive ingredients. PLoS ONE 15(6):e0235076. https://doi.org/10.1371/journal.pone.023507610.1371/journal.pone.0235076 ↗
59. Jones MT et al (2018) Considerations for the use of polysorbates in biopharmaceuticals. Pharm Res 35(8):148. https://doi.org/10.1007/s11095-018-2430-510.1007/s11095-018-2430-5 ↗
60. Cortés H et al (2021) Non-ionic surfactants for stabilization of polymeric nanoparticles for biomedical uses. Materials (Basel) 14(12):3197. https://doi.org/10.3390/ma1412319710.3390/ma14123197 ↗
61. Dwivedi M et al (2018) Polysorbate degradation in biotherapeutic formulations: Identification and discussion of current root causes. Int J Pharm 552(1–2):422–436. https://doi.org/10.1016/j.ijpharm.2018.10.00810.1016/j.ijpharm.2018.10.008 ↗
62. Kaur G, Mehta SK (2017) Developments of polysorbate (Tween) based microemulsions: preclinical drug delivery, toxicity and antimicrobial applications. Int J Pharm 529(1–2):134–160. https://doi.org/10.1016/j.ijpharm.2017.06.05910.1016/j.ijpharm.2017.06.059 ↗
63. Kerwin BA (2008) Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways. J Pharm Sci 97(8):2924–2935. https://doi.org/10.1002/jps.2119010.1002/jps.21190 ↗
64. Schwartzberg LS, Navari RM (2018) Safety of Polysorbate 80 in the oncology setting. Adv Ther 35(6):754–767. https://doi.org/10.1007/s12325-018-0707-z10.1007/s12325-018-0707-z ↗
65. Fiume, M.M. et al. 2019. Safety assessment of sorbitan esters as used in cosmetics. Int J Toxicol. 38(2_suppl), 60S-80S. https://doi.org/10.1177/1091581819871877.10.1177/1091581819871877 ↗
66. Shimanouchi T et al (2021) Microfluidic and hydrothermal preparation of vesicles using sorbitan monolaurate/polyoxyethylene (20) sorbitan monolaurate (Span 20/Tween 20). Colloids Surf B Biointerfaces 205:111836. https://doi.org/10.1016/j.colsurfb.2021.11183610.1016/j.colsurfb.2021.111836 ↗
67. Chen S et al (2019) Recent advances in non-ionic surfactant vesicles (niosomes): Fabrication, characterization, pharmaceutical and cosmetic applications. Eur J Pharm Biopharm 144:18–39. https://doi.org/10.1016/j.ejpb.2019.08.01510.1016/j.ejpb.2019.08.015 ↗
68. Ercole F et al (2015) Cholesterol modified self-assemblies and their application to nanomedicine. Biomacromol 16(7):1886–1914. https://doi.org/10.1021/acs.biomac.5b0055010.1021/acs.biomac.5b00550 ↗
69. Farmoudeh A et al (2020) Methylene blue-loaded niosome: preparation, physicochemical characterization, and in vivo wound healing assessment. Drug Deliv Transl Res 10(5):1428–1441. https://doi.org/10.1007/s13346-020-00715-610.1007/s13346-020-00715-6 ↗
70. Danaei M (2018) Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics 10(2):57. https://doi.org/10.3390/pharmaceutics1002005710.3390/pharmaceutics10020057 ↗
71. Ferreira CD, Nunes IL (2019) Oil nanoencapsulation: development, application, and incorporation into the food market. Nanoscale Res Lett 14(1):9. https://doi.org/10.1186/s11671-018-2829-210.1186/s11671-018-2829-2 ↗
72. Durak S et al (2020) Niosomal drug delivery systems for ocular disease-recent advances and future prospects. Nanomaterials (Basel) 10(6):1191. https://doi.org/10.3390/nano1006119110.3390/nano10061191 ↗
73. Yasam VR et al (2014) A review on novel vesicular drug delivery: proniosomes. Drug Deliv 21(4):243–249. https://doi.org/10.3109/10717544.2013.84178310.3109/10717544.2013.841783 ↗
74. Jug M et al (2018) An overview of in vitro dissolution/release methods for novel mucosal drug delivery systems. J Pharm Biomed Anal 147:350–366. https://doi.org/10.1016/j.jpba.2017.06.07210.1016/j.jpba.2017.06.072 ↗
75. Manaia EB et al (2017) Physicochemical characterization of drug nanocarriers. Int J Nanomedicine 12:4991–5011. https://doi.org/10.2147/IJN.S13383210.2147/IJN.S133832 ↗
76. Ramohlola KE et al (2020) Instrumental techniques for characterization of molybdenum disulphide nanostructures. J Anal Methods Chem 2020:8896698. https://doi.org/10.1155/2020/889669810.1155/2020/8896698 ↗
77. Tiernan H et al (2020) ATR-FTIR spectroscopy and spectroscopic imaging for the analysis of biopharmaceuticals. Spectrochim Acta A Mol Biomol Spectrosc 241:118636. https://doi.org/10.1016/j.saa.2020.11863610.1016/j.saa.2020.118636 ↗
78. Brauner A et al (2016) Distinguishing between resistance, tolerance and persistence to antibiotic treatment. Nat Rev Microbiol 14(5):320–330. https://doi.org/10.1038/nrmicro.2016.3410.1038/nrmicro.2016.34 ↗
79. Roy R et al (2018) Strategies for combating bacterial biofilms: a focus on anti-biofilm agents and their mechanisms of action. Virulence 9(1):522–554. https://doi.org/10.1080/21505594.2017.131337210.1080/21505594.2017.1313372 ↗
80. Caldwell GW et al (2012) The IC(50) concept revisited. Curr Top Med Chem 12(11):1282–1290. https://doi.org/10.2174/15680261280067284410.2174/156802612800672844 ↗
81. Gad, S.C. 2014. LD50/LC50 (lethal dosage 50/lethal concentration 50): In: Wexler P, editor. Encyclopedia of Toxicology (Third Edition). Elsevier Inc, p. 58–60.10.1016/B978-0-12-386454-3.00867-8 ↗
82. Rabin N et al (2015) Biofilm formation mechanisms and targets for developing antibiofilm agents. Future Med Chem 7(4):493–512. https://doi.org/10.4155/fmc.15.610.4155/fmc.15.6 ↗
83. Solano C et al (2014) Biofilm dispersion and quorum sensing. Curr Opin Microbiol 18:96–104. https://doi.org/10.1016/j.mib.2014.02.00810.1016/j.mib.2014.02.008 ↗
84. Macià MD et al (2014) Antimicrobial susceptibility testing in biofilm-growing bacteria. Clin Microbiol Infect 20(10):981–990. https://doi.org/10.1111/1469-0691.1265110.1111/1469-0691.12651 ↗
85. Hamishehkar H et al (2013) Niosomes as a propitious carrier for topical drug delivery. Expert Opin Drug Deliv 10(2):261–272. https://doi.org/10.1517/17425247.2013.74631010.1517/17425247.2013.746310 ↗
86. Sun MC et al (2020) The nano-drug delivery system for the treatment of vitiligo. Int J Nanomedicine 15:3267–3279. https://doi.org/10.2147/IJN.S24532610.2147/IJN.S245326 ↗